Daniel Koller, BB Biotech's head of investment, discusses sector growth, innovation and the attractive valuations of fast-growing companies.
Partner insight At the beginning of 2016, biotech equities were unable to withstand the downward pressure that put financial markets around the globe into bear territory. More recently, movements...
Focus on digital disruption
Taking responsible investing more seriously
Median gender pay gap remains flat at 29%
Deadline for applications: 22 February
Industry Voice: Today Lyxor ETF interviews Lorenzo Bini Smaghi, Societe Generale Chairman and formerly "Italy's man at the ECB".